Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FES-PET imaging to detect ERα status reversion in HER2-positive, ERα-negative metastatic breast cancer treated with trastuzumab + pertuzumab + taxane
2018-001552-36Phase 2Terminated
- Sponsor
- Institut Claudius Regaud
- Start
- Jul 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab and pertuzumab in breast cancer, sponsored by Institut Claudius Regaud. Primary endpoint: Conversion rate of FES-PET lesions from FES-negative to FES-positive. Started Jul 2018; status: terminated.
02
Drugs
trastuzumabpertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on 2018-001552-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001552-36.